About this trial
Fabry disease is a rare genetic disorder affecting 1 in 10,000 individuals, leading to complications such as chronic pain, heart and kidney failure, and strokes, ultimately impacting life expectancy. People with this disease are increasingly being diagnosed later in life, around the age of 65, as the condition progresses slowly with irreversible organ damage. The effectiveness of treatments for Fabry disease remains controversial, but early initiation is recommended for long-term benefits. Despite the high cost and inconvenience of treatments, there is limited research on their efficacy in older people or on the quality of life for those aged 65 and over with Fabry disease. This study aims to assess the quality of life in this age group both with and without treatment over a period of 5 years to determine the benefits of treatment beyond the age of 65.
Eligibility criteria
Qualifiers
Men and women aged 65 and over with a diagnosis of Fabry disease with, for men, a proven alpha-galactosidase A deficiency or an identified pathogenic GLA genetic variant, and for women, an identified pathogenic GLA variant.
Minimum work-up available: ECG, 24h holterECG, cardiac ultrasound, creatinemia, proteinuria and/or microalbuminuria.
Have received written and oral information about the protocol and have not expressed any opposition to participating in the study.
Affiliated to a social security scheme or entitled to benefits (excluding AME).
Disqualifiers
Inability to understand the information provided,
Under guardianship, curatorship or safeguard of justice,
Under restraint or deprived of liberty by judicial or administrative decision.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Wladimir MAUHIN, Dr
Lead sponsor
Groupe Hospitalier Diaconesses Croix Saint-Simon
Sponsor institution
University Hospital, Angers
Collaborator
University Hospital, Bordeaux
Collaborator
Centre Hospitalier Bretagne Atlantique
Collaborator
Centre Hospitalier Universitaire de Caen
Collaborator
University Hospital, Clermont-Ferrand
Collaborator
Centre Hospitalier Universitaire Dijon
Collaborator
University Hospital, Lille
Collaborator
University Hospital, Limoges
Collaborator
University Hospital, Marseille
Collaborator
Nantes University Hospital
Collaborator
Hôpital Necker-Enfants Malades
Collaborator
Rennes University Hospital
Collaborator
University Hospital, Tours
Collaborator
Hôpital Raymond Poincaré
Collaborator
University Hospital, Rouen
Collaborator
Hospital, Vannes
Collaborator
University Hospital, Brest
Collaborator
University Hospital, Grenoble
Collaborator
University Hospital, Strasbourg
Collaborator
Hospices Civils de Lyon
Collaborator
Centre Hospitalier de la côte Basque
Collaborator
University Hospital, Montpellier
Collaborator
Centre Hospitalier Universitaire de Nice
Collaborator